Skip to main content
PLOS One logoLink to PLOS One
. 2012 Feb 1;7(2):10.1371/annotation/cb50dce6-fca7-47b1-b94b-ae21619f26f3. doi: 10.1371/annotation/cb50dce6-fca7-47b1-b94b-ae21619f26f3

Correction: Mangafodipir Protects against Hepatic Ischemia-Reperfusion Injury in Mice

Romain Coriat, Mahaut Leconte, Niloufar Kavian, Sassia Bedda, Carole Nicco, Christiane Chereau, Claire Goulvestre, Bernard Weill, Alexis Laurent, Frédéric Batteux
PMCID: PMC3273933

There was an error in the Competing Interests declaration. The authors did not declare several potential competing interests relevant to the work reported. They apologize for the omission and would like to disclose the following information: Drs Batteaux and Weill are the founders of Protexel, an R&D company aiming to develop mangafodipir as a commercial drug. Drs Batteaux and Weill are co-inventors of patents describing mangafodipir as a liver-protective and anti-cancer agent.

Footnotes

Competing Interests: No competing interests declared.


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES